Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$33.25
-0.2%		$33.54
$22.24
▼
$46.00
$1.99B0.6890,870 shs1.25 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.78
+1.0%		$39.40
$15.95
▼
$45.42
$6.91B0.811.47 million shs1.43 million shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$44.65
-2.7%		$54.44
$43.01
▼
$86.74
$7.63B0.424.55 million shs2.53 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$89.03
+5.1%		$96.09
$15.86
▼
$110.18
$7.45B2.991.16 million shs2.10 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-0.15%-2.75%-1.28%-11.52%-17.16%
Immunovant, Inc. stock logo
IMVT
Immunovant
+0.96%-2.20%-17.25%-12.92%+109.55%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-2.70%+1.64%-26.03%-45.42%-31.75%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+5.09%+0.98%-0.34%+2.77%+431.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$33.25
-0.2%		$33.54
$22.24
▼
$46.00
$1.99B0.6890,870 shs1.25 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.78
+1.0%		$39.40
$15.95
▼
$45.42
$6.91B0.811.47 million shs1.43 million shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$44.65
-2.7%		$54.44
$43.01
▼
$86.74
$7.63B0.424.55 million shs2.53 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$89.03
+5.1%		$96.09
$15.86
▼
$110.18
$7.45B2.991.16 million shs2.10 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-0.15%-2.75%-1.28%-11.52%-17.16%
Immunovant, Inc. stock logo
IMVT
Immunovant
+0.96%-2.20%-17.25%-12.92%+109.55%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-2.70%+1.64%-26.03%-45.42%-31.75%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+5.09%+0.98%-0.34%+2.77%+431.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.55
Moderate Buy$41.7525.56% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.58
Moderate Buy$44.0030.25% Upside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.73
Moderate Buy$89.2099.78% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.87
Moderate Buy$109.6923.21% Upside

Current Analyst Ratings Breakdown

Latest AGIO, SYRE, IONS, and IMVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/24/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$85.00
9/24/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$76.00 ➝ $70.00
9/21/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/21/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$46.00 ➝ $50.00
9/15/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$89.00 ➝ $80.00
9/9/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$90.00 ➝ $85.00
9/9/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$123.00
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$98.34M20.19N/AN/A$20.46 per share1.63
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$874.09M8.49N/AN/A$3.02 per share14.78
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K8,796.96N/AN/A$7.21 per share12.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$412.78M-$7.01N/AN/AN/A-418.24%-35.67%-33.06%10/29/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$3.46N/AN/AN/A-64.76%-111.08%-17.41%11/4/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$1.95N/AN/AN/AN/A-30.74%-22.23%11/3/2026 (Estimated)

Latest AGIO, SYRE, IONS, and IMVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.21N/AN/AN/A$53.81 millionN/A
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/4/2026Q2 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7589-$0.36+$0.3989-$0.36N/AN/A
7/30/2026Q2 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.65-$1.69-$0.04-$1.69$26.40 million$44.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
10.22
9.79
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3.07
7.89
7.73
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
18.53
18.53

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
5.40%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1.81%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
54059.70 million56.48 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.55 million202.63 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402166.18 million163.18 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
11287.94 million74.14 millionOptionable

Recent News About These Companies

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Time to Buy?
September 30 at 11:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-spyre-therapeutics-nasdaq-syre-shares-gap-up-time-to-buy-2026-09-30/
Spyre Therapeutics, Inc. (SYRE)
September 29 at 7:40 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SYRE/chart/
Analyzing Surrozen (NASDAQ:SRZN) & Spyre Therapeutics (NASDAQ:SYRE)
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044583
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by Brokerages
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034152
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-syre-clears-monotherapy-phase-070453140.html
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Moderate Buy" from Analysts
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-spyre-therapeutics-inc-nasdaq-syre-receives-average-rating-of-moderate-buy-from-analysts-2026-09-15/
California State Teachers Retirement System Increases Stake in Spyre Therapeutics, Inc. $SYRE
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-5683670-shares-of-spyre-therapeutics-inc-syre-2026-09-15/
Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-takes-342-million-position-in-spyre-therapeutics-inc-syre-2026-09-14/
11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-11250-shares-in-spyre-therapeutics-inc-syre-acquired-by-virginia-retirement-systems-et-al-2026-09-14/
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
September 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/spyre-therapeutics-syre-reports-spy003-endoscopic-improvement-can-randomized-testing-confirm-it-1835858/
Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-invests-1239-million-in-spyre-therapeutics-inc-syre-2026-09-10/
Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-takes-position-in-spyre-therapeutics-inc-syre-2026-09-10/
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944572-spyre-therapeutics-inc-syre-presents-at-citigroups-biopharma-back-to-school-summit-2026
Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results
September 9, 2026  |  blockonomi.comhttps://blockonomi.com/spyre-therapeutics-syre-stock-surges-as-guggenheim-declares-it-top-biotech-following-uc-trial-results/
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
September 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2987021/spyre-s-anti-il-23-antibody-meets-goal-in-ulcerative-colitis-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2987021
Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reiterates-outperform-rating-for-spyre-therapeutics-nasdaq-syre-2026-09-09/
Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-maven-securities-ltd-invests-355-million-in-spyre-therapeutics-inc-syre-2026-09-09/
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-from-skyline-trial-completing-proof-of-concept-for-all-three-components-of-its-ibd-combinations-1036528172
Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis
September 8, 2026  |  rttnews.comhttps://www.rttnews.com/3689162/spyre-therapeutics-reports-positive-phase-2-spy003-data-in-ulcerative-colitis.aspx
Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-apos-spy003-meets-133515544.html
Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-spyre-therapeutics-syre-buy-rating-reiterated-at-btig-research-2026-09-08/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Large haul trucks travel a winding road through an open-pit mine at sunrise or sunset.
Bond Yields Are Pressuring Gold, But Miners May Tell a Different Story
By Jeffrey Neal Johnson | September 8, 2026
Laptop displaying a U.S. Treasury yield curve chart on a desk with monitors showing stock market data.
3 ETFs That Could Move as Rate Expectations Shift
By Dan Schmidt | September 6, 2026
A drone with a camera gimbal flies in a dark room above the Draganfly company logo.
Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
By Jeffrey Neal Johnson | September 1, 2026
Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$33.25 -0.05 (-0.15%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$33.27 +0.02 (+0.06%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$33.78 +0.32 (+0.96%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$33.74 -0.04 (-0.10%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$44.65 -1.24 (-2.70%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$44.96 +0.31 (+0.69%)
As of 09/30/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$89.03 +4.31 (+5.09%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$88.11 -0.92 (-1.03%)
As of 09/30/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas